After being treated with direct-acting antivirals, African Americans with hepatitis C are less likely to achieve sustained virologic response at 12 weeks (SVR12) compared with white patients, according to results published in Pharmacology Research & Perspectives.
Patients with hepatitis C who have advanced fibrosis are also less likely to achieve SVR12 than patients who do not have fibrosis.
After adjusting for variables, the researchers found that race/ethnicity and the presence of fibrosis were statistically significant predictors of non-SVR. African American participants had 57% lower odds for reaching SVR12 (adjusted OR 0.43; 95% CI, 1.5-4.1) compared with white participants. Advanced fibrosis (adjusted OR 0.40; 95% CI, 0.26-0.68) was also a significant predictor of non-SVR.